What We Have Learned—Milestones in Pediatric Contact Dermatitis

Elizabeth Dupuy1 · Melanie Miller2 · Nicole Harter3,4

Accepted: 6 January 2022 / Published online: 26 March 2022 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract

Purpose of Review This review highlights recent developments in the field of pediatric allergic contact dermatitis (ACD) and patch testing. We will review updates on the pathophysiology of contact dermatitis, discuss new contact allergens, explore the impact of dupilumab on patch testing, and provide pearls for the diagnosis and management of ACD in children.

Recent Findings ACD is not a single immunologic phenomenon but rather has contributions from multiple inflammatory pathways. Emerging contact allergens include ingredients found in “slime” toys, glucose monitors and insulin pumps, and electronic equipment. Data thus far suggests that patch testing results are generally reliable in the face of concurrent dupilumab use.

Summary ACD is likely underrecognized and underdiagnosed in pediatric patients, including infants and young children. Providers should keep patient-specific factors and emerging trends in mind when addressing suspected ACD, consider contact dermatitis when they encounter challenging cases of atypical, refractory, or chronic dermatitis, and feel comfortable performing patch testing in children.

Keywords Pediatric allergic contact dermatitis · Irritant contact dermatitis · Patch testing · Pediatric allergens

Introduction

Contact dermatitis is a common inflammatory skin disease, the etiology of which can be categorized as allergic or irritant. While irritant contact dermatitis is understood to widely affect children, it is a common and historical misconception that allergic contact dermatitis (ACD) is rare in children. As this article aims to highlight, ACD is relatively prevalent in the pediatric population. Patients with contact dermatitis may also have a concomitant primary dermatitis, such as atopic dermatitis, which can make the diagnosis of contact dermatitis even more challenging to reveal. Both pediatric and adult dermatologists should be able to recognize the prevalence, patterns, and allergens/irritants relevant to the pediatric population. This knowledge can significantly impact clinical management in children with atypical, treatment refractory, and/or chronic dermatitis.

Here, we will briefly review the latest data from the past 5 years concerning contact dermatitis in the pediatric patient, with a focus on ACD, including the most common and emerging contact allergens relevant to children, specific nuances of patch testing, and prevention strategies. We will also review the evolving role tele-dermatology may play in the future diagnosis and management of contact dermatitis.

Pediatric Irritant vs. Allergic Contact Dermatitis

There are two forms of contact dermatitis, irritant contact dermatitis (ICD) and ACD. ICD, which is caused by direct injury to the skin by an irritating or toxic substance, does not require prior sensitization and will develop in any individual with sufficient concentration and exposure time. This injury activates the innate immune system and results in an
inflammatory response [1]. ICD is a more frequent cause of contact dermatitis than ACD, accounting for approximately 80% of cases [1]. Unlike ACD, ICD usually remains confined to the specific anatomic location of injury.

Examples of irritant dermatitis specific to children include perineal dermatitis from soiled diapers, perennial dermatitis from saliva, and hand dermatitis secondary to washing or sanitizers [2••]. During the COVID-19 pandemic, the American Contact Dermatitis Society (ACDS) published recommendations for hand hygiene recognizing the important balance between infection prevention and dermatitis. Overall, alcohol-based hand sanitizers with moisturizers were recommended given the decreased risk for sensitization and irritation when compared with soaps and detergents [3].

In contrast to ICD, ACD is a type IV delayed-type hypersensitivity reaction, which occurs in two phases: sensitization and elicitation. The sensitization phase occurs when allergens cross the epidermal barrier and are encountered by Langerhans cells or dermal dendritic cells which recognize them as foreign [1]. These antigen-presenting cells then migrate to regional lymph nodes where naïve T-cells are activated, resulting in proliferation of allergen-specific T-cells in the peripheral circulation [1, 4]. In the subsequent elicitation phase, an allergen again contacts the skin and a sensitized specific T-cell recognizes it and activates the inflammatory response that ultimately leads to skin symptoms at the site of exposure [1, 4]. In ACD, the dermatitis can expand outside the confines of initial contact, and there may be hours to days between the contact and development of symptoms [5•].

For many years, it was believed that ACD was a TH1-skewed immune response. A study by Dhingra et al. looked at the molecular and cellular profiles of patch tested skin and demonstrated differential immune responses induced by different allergens [6•]. For example, fragrance induced expression of TH2-related genes, whereas nickel induced TH17- and TH1-related genes [6•]. Although the exact mechanisms are not well understood, it is now accepted that ACD is not a single immunologic phenomenon, but rather has contributions from multiple pathways, including TH1, TH2, TH17, and TH22 [6•].

**Pediatric Allergic Contact Dermatitis**

ACD has previously been described as an uncommon occurrence in children, and however, more recent data suggests prevalence rates of 16.5% (or higher), as compared with 21.4% in adults [2••, 4, 7–10]. Recent studies have found that positive patch test (PPT) rates in the pediatric population are comparable to adults, with up to 65% of pediatric patients referred for patch testing having one or more positive reactions, half of which are clinically relevant [2••, 11•]. Contributing factors for allergen exposures in children include cleansing and bathing habits, dressing habits, exposure to jewelry and other metals, personal care products, outdoor and indoor activities, and relevant history of other dermatological conditions such as atopic dermatitis. There are overall lower rates of patch testing done in the pediatric population compared to adults, suggesting decreased referral rates for patch testing and potentially underdiagnosis [2••, 12].

Etiologies of ACD in children are very diverse – important considerations include medications, personal care products, toys, sports, activities, and hobbies, as well as products used by parents and caregivers. The top allergens in children have been described consistently in numerous registries and reviews, and are summarized in Table 1 [2••, 11•, 13].

**Nickel**

Nickel is omnipresent in our world and is the most common clinically relevant PPT in both children and adults. Nickel is responsible for up to 24% of PPTs in children (ranges of 8–28%), of which 69% are clinically relevant [14•]. Items containing nickel include coins, jewelry, toys, cellphones, computer parts, video game consoles, paints, musical instruments, belts, and clothing. Nickel can also be present in food and may cause systemic contact dermatitis. The most relevant nickel in ACD is “free nickel,” or the amount of nickel released from a product [14•]. Female pediatric patients are 50% more likely to have a PPT against nickel, likely due to early jewelry exposure. Nickel sensitivity is also correlated with total number of piercings in both males and females [15]. In 1994, European regulations were put in place to control the amount of nickel in consumer products. European countries that adopted nickel regulations in the early 1990s have saved an estimated $2 billion in healthcare costs due to nickel contact dermatitis. Similar regulations have not been implemented in the United States (US) [14•]. In 2011, after the development of the nickel workgroup and resolutions adopted by the American Academy of Dermatology (AAD),

| Table 1 | Top pediatric contact allergens in the United States |
|---|---|
| Category | Allergen |
| Metals | Nickel, cobalt |
| Fragrances | Fragrance mix I & II, balsam of Peru |
| Emollients/surfactants | Propylene glycol, cocamidopropyl betaine, lanolin |
| Topical antibiotics | Bacitracin, neomycin |
| Preservatives | MCI/MI, MI, formaldehyde (releasers) |

Adapted from Neale et al. [2••, 50••]

*MC1/MI methylchloroisothiazolinone/methylisothiazolinone, MI methylisothiazolinone*
the American Society for Testing and Materials (ASTM) adopted a voluntary safety standard for nickel, and however, many companies have yet to adopt these guidelines [14•]. More recently, in 2015, the Nickel Allergy Alliance was created and, in conjunction with the AAD, continues to push for mandatory regulations of nickel in the US. They suggest that with further regulation of nickel in products, there is a potential avoidance of $5.7 billion per year in healthcare costs related to nickel dermatitis [14•].

**Cobalt**

Cobalt is another metal that is a repeated cause of ACD in the pediatric population. It is compounded with nickel and patients are often co-sensitized to both after exposure to metal-plated items including jewelry, toys, and clothing items. Rarely children can develop ACD to cobalt alone [2••]. Other potential exposures in the pediatric population include blue/green crayons and paints (as cobalt is often used as a pigment) and leather items, including shoes [7].

**Fragrance**

Fragrances are some of the top contact allergens in the pediatric population. Fragrance allergy is commonly screened for using fragrance mix I/II and balsam of Peru (BoP), although this is a large category including numerous different allergens [2••, 4]. Exposure often occurs with personal care products, detergents, and perfumes (which can be by proxy from a parent/caregiver/sibling) [16]. Fragrance can also be used as “masking” fragrance to mask a product’s unpleasant smell for an overall neutral smell. Recent studies have found that cosmetic products marketed toward babies and infants and labeled as “hypoallergenic” and even “fragrance-free” often contained fragrances [16, 17]. Unfortunately, in North America, personal care product labels are not required to list anything more specific than “fragrance” or “parfum,” thus sensitized patients have to practice broad avoidance of all products containing fragrance.

**Formaldehyde and Formaldehyde Releasers**

Formaldehyde itself is no longer used in personal care products in the European Union however can still be found in some products in the US and is a common allergen in the pediatric population. While “formaldehyde” will never be included in the ingredients list, a number of formaldehyde-releasing preservatives, including quaternium-15, imidazolidinyl urea, diazolidinyl urea, DMDM hydantoin, and Bronopol (2-bromo-2-nitropropane-1,3-diol), are found in personal care products and can be allergens as well. Bronopol is the most common of these preservatives to cause ACD in children [4].

**Methylchloroisothiazolinone/Methylisothiazolinone**

Methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) is a preservative that is widely used in a variety of personal care products, paints, solvents, and cleaning products. The combination of MCI/MI has been a cause of ACD in personal care products for decades, though more recently, MI was introduced alone in much higher concentrations, which led to an increase in allergic contact diaper dermatitis due to its presence in baby wipes [18]. The European Union strictly regulated the use of these preservatives in consumer products, whereas no similar legislation has been enacted in North America. Nonetheless, it would seem manufacturers have taken notice, considering a recent study showing that nearly no popular, readily available baby wipes contain MI or other isothiazolinone derivatives [18]. However, MI is still used as a preservative in many personal care products marketed toward children, which supports data showing an increase in MI ACD from non-wet wipe products [18, 19]. In 2020, MI was reported as the culprit in ACD to children’s nail polish, as well as a cause of airborne contact dermatitis from a child’s water-based paint, household paint, and a cleaning product [20, 21]. MCI/MI is also a common source of “slime dermatitis,” which is discussed in greater detail below [22].

**Cocamidopropyl Betaine**

Cocamidopropyl betaine (CAPB) is a surfactant commonly found in rinse-off products (shampoos, soaps, body washes) and has been described as a common yet underrecognized cause of ACD in children, with upward of 3% of children being reported as sensitized to the allergen [16, 23]. In one Polish study, CAPB was present in 30% of the analyzed 212 skin care products marketed for children 0–12 months of age [16]. It was also found to be an ingredient in a high proportion of “hypoallergenic” personal products for children [24]. Studies have also suggested a greater incidence of sensitization to CAPB in patients with atopic dermatitis [25].

**Lanolin**

Lanolin is derived from sheep’s wool and is frequently used as an emollient in personal care products, with reports citing its presence in 9% of cosmetics [16]. Lanolin may cause ACD even in very young children, with sensitization rates cited at 1.2–6.2% of pediatric patch test patients [9, 23, 26]. Lanolin is a common allergen in those with atopic dermatitis likely due to their frequent and early exposure to emollients and skin care products [4, 9].
**Propylene Glycol**

Propylene glycol (PG) is a synthetic alcohol commonly used as an emollient, emulsifier, solvent, and antimicrobial. It was named the ACDS Allergen of the Year in 2018 [27]. It is a common ingredient in cosmetic skin care products, topical medications (including steroid creams), household cleaners, and foods. It is both an irritant and a weak sensitizer, spurring debate as to which concentration and vehicle is ideal for patch testing, and calling into question the significance of positive patch test results [27]. PG is ubiquitous and was reported to be present in more than 37% of over 4500 products in the ACDS’s 2016 Contact Allergen Management Program (CAMP) database [28]. According to the Pediatric Contact Dermatitis Registry (PCDR), of the 1142 US pediatric patch tests performed between 2015 and 2016, PG was the fifth most prevalent contact allergen, identified in 6.8% of children tested [27]. It is also a potential cause of rare cases of systemic contact dermatitis [27].

**Topical Antibiotics**

Topical antibiotics, particularly neomycin and bacitracin, are frequently used for the treatment and prevention of superficial skin infections. These medications are readily available over the counter in the United States, thus contributing to high rates of sensitization in children [29]. Neomycin has been in the list of top pediatric allergens for several decades [29]. Topical antibiotics are known to cause delayed patch test reactions which can appear as late as 3 weeks, therefore, if suspicion is high, a delayed reading should be considered [30].

**ACD and Neonates/Infants**

Previously, it was postulated that neonates were unlikely to develop ACD given their immature immune systems, but this has proven to be false. Neonates may be particularly vulnerable due to their decreased epidermal barriers and product exposures. With respect to the development of ACD, there are two prevalence peaks within early childhood, between 0–3 years and 6–7 years [11•].

Diaper dermatitis is a common skin condition of the neonate and can have numerous etiologies, the most common being ICD. Despite this, ACD is likely underrecognized and underdiagnosed in both diaper dermatitis and perineal dermatitis. It is hypothesized that the irritant dermatitis leading to skin breakdown in the perineal/diaper area can lead to increased risk of sensitization to allergens and subsequent ACD. Studies have found numerous allergens in diapers and diaper wipes [31•, 32]. While MCI/MI has largely been eliminated from wet wipes/diaper wipes, reports have documented numerous other and emerging allergens [18]. Many products listed as “hypo-allergenic” or “safe for babies” contain allergens such as cocamidopropyl betaine, tocopherol, propylene glycol, fragrances, lanolin, Compositae family, and other botanical extracts, which have proven to be culprit allergens in diaper dermatitis due to ACD [32].

**ACD and Atopic Dermatitis**

Atopic dermatitis (AD) is the most prevalent skin condition in the pediatric population. Its pathogenesis is multifactorial but is defined as a Th2-mediated disease commonly featuring mutations in filaggrin, leading to disruption of the epidermal barrier. ACD in the setting of AD has been explored extensively in the literature and the association of these conditions is controversial. For now, it seems that patients with AD have at least similar risk of developing ACD compared to non-AD patients. Several factors may put patients with AD at risk of ACD, including increased early sensitization to personal care products, decreased epidermal barrier function, and cross-over of Th2 to Th1-helper T-cells [5•].

Studies have found that patients with moderate-to-severe, uncontrolled AD often have more false-negative patch tests. It has been hypothesized that while AD is acute and active, the immune response is skewed toward a Th2 response, and however, once AD is controlled and in a more chronic phase, this leads to Th1 skewing, and more frequent PPTs. Additionally, patients with AD have an impaired skin barrier which results in greater absorption of potential allergens. Studies of moderate-to-severe AD patients showed more PPT to weaker allergens in personal care products as compared to healthy controls, suggesting increased absorption into the skin of those with AD [5•, 31•, 32].

A large review of the PCDR found that up to half of patients with ACD had a previous diagnosis of AD. Patients with AD were more likely to have been patch tested earlier in life, and were more likely to test positive to common allergens in personal care products including topical emollients [5•, 31•, 33]. In the PCDR study, Jacob et al. found the most common allergen in the AD patient population to be nickel, followed by fragrance mix and balsam of Peru, similar to the non-AD patient population. However, there were some notable differences compared to non-AD patients. AD patients were more likely to test positive to five allergens: CAPB, wool alcohol, lanolin, tixocortol pivalate (tester for corticosteroids class A which cross-reacts with class D2), and parthenolide. This is hypothesized to be due to early exposure to emollients and topical medications in the setting of treatment for AD. Interestingly, patients with AD had statistically significant lower rates of PPT to MCI/MI than non-AD patients. This may be secondary to MCI/MI’s action as a potent sensitizer, which classically induces
a robust Th1 response, and may be dampened in those with a Th1/Th2 imbalance, as present in uncontrolled AD [31•].

**New Sources of Pediatric ACD**

The COVID-19 pandemic has had lasting effects on all areas of medicine. With children spending significantly more time at home and parents inventing creative ways to entertain them, one can predict that various at-home activities may lead to upticks in ACD due to certain pediatric allergens. Emerging pediatric ACD trends over the past few years include slime dermatitis, gaming dermatitis, and dermatitis due to diabetes devices.

**Slime Dermatitis**

Originally made famous by Slimer in the movie Ghostbusters, slime is a popular toy composed of a semi-viscous, sticky goo or gel, which in recent years has been popularized as a make-at-home activity for kids. Social media sites, including Instagram, YouTube, and TikTok, have made it easy to share slime recipes. In 2019, as autonomous sensory meridian response (ASMR) videos were popularized on these platforms, viewing slime videos became a popular trend. On TikTok alone, there are 15.9 billion views for the hashtag “slime.” Subsequently, slime dermatitis became an emerging pediatric ACD trend in 2017. Slime ingredients can vary based on the recipe but include both potential irritants and contact allergens. The base ingredients include a detergent, such as shampoo, soap, or laundry detergent, in addition to boric acid, which are both causes of ICD. Most slime recipes also include glue which can contain numerous contact allergens, including isothiazolinones [22, 34, 35]. A 2019 case report described the most common slime recipes on the internet and cited numerous other potential allergens, including propylene glycol, paraben mix, benzyl alcohol, cocamidopropyl betaine, triethanolamine, compositae mix, parthenolide, sesquiterpenes lactone, diazolidinyl urea, DMDM hydantoin, sodium hydroxymethylglycinate, stearyl alcohol, cetearyl alcohol, cetyl alcohol, and tocopheryl acetate [22]. Of note, many of the potential allergens in slime are not present on the T.R.U.E. Test, but have been listed in the Pediatric Baseline Patch Test Series [22].

**Gaming/Electronics Dermatitis**

Other potential allergen exposures during the COVID-19 pandemic include those related to increased electronic use, ranging from computers to tablets to cell phones. Video games that allow social interaction during this isolating period are more popular than ever. Many consoles and electronics contain nickel and other metals [14•]. There are case reports of ACD due to cell phone use caused by high amounts of nickel released from the device and more recently isobornyl acrylate (IBOA) released from cell phone screen protectors in the occupational setting [36]. The literature also describes ACD in adults to computer mouses, mouse pads, and keyboards, as these items often contain rubber compounds (i.e., dialkyl thiourea or neoprene) and various plastics. In 2018, a case was reported of a 12-year-old who developed an eczematous plaque at the site where his forearm rested on the metal hinge of his computer gaming desk, which was found to contain nickel [37]. We suspect upticks in these types of clinical presentations, which require detailed and thorough histories in the evaluation of the patient with suspected ACD.

**Diabetes Device Dermatitis**

Treatment of type 1 diabetes mellitus (T1DM) in children has advanced significantly with the development of continuous subcutaneous insulin infusions (CSIIs), continuous glucose monitors (CGMs), flash glucose monitors (FGMs), and sensor augmented pumps (SAPs). Use of these devices has been shown to improve overall glycemic control [38]. However, with these new technologies has come a new wave of ACD. These systems require adhesives and prolonged skin contact time at sites of monitors and insulin pumps (sometimes up to 14 days). Dermatologic complications during T1DM management are not rare; it is estimated that anywhere between 33 and 90% of children using these devices develop skin rashes, including ACD [39, 40]. In children with T1DM using these devices, there is no known correlation between the development of ACD and duration of diabetes or degree of control of blood glucose levels [41].

Allergens found in diabetes devices include IBOA, ethyl cyanoacrylate, N,N-dimethylacrylamide (DMAA), and colophony (Table 2) [38–42]. IBOA is an acrylate highly utilized in medical devices as an adhesive. In the context of T1DM treatment, IBOA was found to be a component of the FreeStyle Libre glucose monitor’s housing, rather than the adhesive portion. Subsequently, the presence of IBOA was confirmed in several other glucose monitors and insulin pumps. In 2020, IBOA was selected as the ACDS Contact Allergen of the Year to raise awareness of its presence in medical devices and increasing rates of sensitization. Manufacturers of these systems have not often been forthcoming about the components of their sensors and monitors, though some have confirmed the presence of allergens within their devices. More recently, in the spring of 2019, the FreeStyle Libre 2 was introduced and marketed as IBOA free, suggesting that IBOA-sensitized patients may be able to use this device, and however, further observations are necessary [43]. They may also have the option to switch their CGM to Dexcom
DMAA

N,N-dimethylacrylamide

monitor, continuous subcutaneous insulin infusion, CSII et al. [42]

Hartsough and Hylwa [38], Lombardo et al. [41], Raison-Peyron gens

continuous using their preferred diabetes devices despite the plate, Convatec, Deeside, UK) have allowed patients to BSN Medical, Hamburg, Germany; and Stomahesive base last, Beiersdorf, Hamburg, Germany; Cutimed Hydro B, to prevent ACD from IBOA. These products (i.e., Hansap-

barrier dressings such as Tegaderm (3 M, St. Paul, MN), for several days prior to use. We have attempted the use of sparing agents, such as tacrolimus ointment, to sites application of topical steroid foam, spray, solution, and oil appropriately to the skin. We have also attempted pre-device run into difficulty with these devices then adhering appro-

omnipod and Dexcom systems in our clinics. We cur-

tentially rotating the body site of application for the Omnipod and Dexcom systems in our clinics. We cur-

BMI to a device that does not contain the culprit allergen, or use more traditional methods for subcutaneous insulin injec-

G4/G5 or Eversense; however, there is not a clear IBOA-

free alternative to the Omnipod insulin pump. Colophony, DMAA, and ethyl cyanoacrylate are used in medical-grade adhesives and have also caused ACD related to diabetes devices.

Anecdotally, we have managed suspected ACD due to the Omnipod and Dexcom systems in our clinics. We currently recommend rotating the body site of application for both the CGM and CSII, while using topical corticosteroids to these sites after use, and preemptively using steroid-sparing agents, such as tacrolimus ointment, to sites for several days prior to use. We have attempted the use of barrier dressings such as Tegaderm (3 M, St. Paul, MN), Duoderm (Convatec, Oklahoma City, OK), and barrier film/spray/cream (Cavilon, 3 M, St. Paul, MN) beneath the site of monitor and/or sensor applications, however have run into difficulty with these devices then adhering appropri-

tely to the skin. We have also attempted pre-device application of topical steroid foam, spray, solution, and oil of varying potencies without success due to same difficulty in subsequent adhesion of the diabetes device. Encour-

agingly, there are newer reports of patients successfully using hydrocolloid blister plaster beneath diabetes devices to prevent ACD from IBOA. These products (i.e., Hansaplast, Beiersdorf, Hamburg, Germany; Cutimed Hydro B, BSN Medical, Hamburg, Germany; and Stomahesive base plate, Convatec, Deeside, UK) have allowed patients to continue using their preferred diabetes devices despite the development of ACD [44, 45]. There is currently no consensus on how to treat these patients or how to resolve the emerging problem with these devices, other than to switch to a device that does not contain the culprit allergen, or use more traditional methods for subcutaneous insulin injec-

Table 2 Insulin pumps, glucose monitors, and relevant contact allergens

| Brand (Manufacturer) | Device category | Reported allergen |
|----------------------|-----------------|-------------------|
| Omnipod (Insulet)    | CSII            | IBOA, colophony   |
| FreeStyle Libre (Abbott) | FGM          | IBOA*, DMAA*      |
| Dexcom G4 (Dexcom)   | CGM             | Ethyl cyanoacrylate |
| Dexcom G6 (Dexcom)   | CGM             | IBOA**            |
| Enlite (Medtronic)   | CGM             | IBOA, DMAA, colophony |

* Absent from FreeStyle Libre 2
** Absent from Dexcom G5

Limonene and Linalool

Limonene and linalool are natural terpenes found in oils, fruits, trees, grasses, and tobacco [46]. Oxidation of limonene and linalool results in allergenic hydroperoxides that have been increasingly implicated in pediatric ACD [47]. More recently, linalool and limonene have been found to be prevalent in many personal care products and deter-

genents used in children. Linalool has been found in 90% of common essential oils, which are frequently applied directly to the skin or diffused, in which case they may cause an air-

borne contact dermatitis. Testing of limonene/linalool alone is unreliable in detection of ACD; their hydroperoxides must be included in patch testing to yield pertinent data. Notably, these hydroperoxides are not included in available patch test fragrances mixes and must be tested separately. A recent retrospective review found that these allergens were tested less than half the time in the pediatric population [48]. The review also found that among patients who tested positive to limonene/linalool, more than 50% also tested negative to fragrance mix I/II or balsam of Peru, thus it has been re-

commended that hydroperoxides of limonene/linalool should be tested in anyone suspected of having fragrance allergy. Limonene/linalool are reported to induce false-positive irritant reactions on patch testing, therefore a delayed reading on day 7 could be considered to attempt to discern a true-

positive from an irritant reaction [46–48]. The evolving data on limonene, linalool, and their allergenic hydroperoxides further highlights the importance of understanding the partic-

ular and nuanced allergens applicable to our pediatric patients.

Shin Guard Dermatitis

The 2021 Contact Allergen of the Year is also relevant to the pediatric population. Acetophenone azine is a recently discovered allergen that is generated during the manufac-

tering process of products made of ethylene vinyl acetate (EVA)-based copolymer foam. There have been multiple case reports of shin dermatitis due to acetophenone azine in soccer shin pads. It is likely that acetophenone azine ACD was the culprit in some cases of shin guard dermatitis previously diagnosed as ICD. In addition, this allergen has been reported in flip flops and other shoes [49].

Pediatric Patch Testing

Patch testing is the gold standard in the diagnosis and man-

agement of ACD in patients of all ages. Conducting patch testing in children presents unique challenges. Please refer to Table 3 for recommendations and special considerations in patch testing in children.
The thin-layer rapid-use epicutaneous patch test (T.R.U.E. Test, SmartPractice Denmark, Hillerød, Denmark) was first FDA-approved for adults in 1994 and received approval in 2017 for use in children 6–17 years of age after a prospective study of 100 patients showed a low rate of adverse events and demonstrated efficacy based on self-reported improvement following testing [25, 50••]. This test includes 35 allergens and 1 negative control separated into three panels [25]. Limitations of the T.R.U.E. Test are the exclusion of important pediatric contact allergens including cocamidopropyl betaine, propylene glycol, fragrance mix II, and decyl glucoside [25, 51]. Notably, up to 37% of patients could test false-negative on patch testing to MCI/MI with the T.R.U.E. Test due to low concentration of MI in this commercially available patch testing product [50••]. In contrast, the ACDS Core and North American Contact Dermatitis Group (NACDG) series test MCI/MI as well as MI alone at higher concentration, which more often elicits a true PPT, thus reducing false-negative reactions.

A retrospective cohort study of pediatric patients evaluated for ACD using the more inclusive North American 80 Comprehensive Series demonstrated that almost half of the positive reactions were to allergens not included in the T.R.U.E. Test [25]. Of the 10 most common allergens with positive reactions in this study, three – CAPB, benzoyl peroxide, and propylene glycol – are not in the T.R.U.E. Test [29]. Especially important is the exclusion of CAPB given its high allergy prevalence – 4% in one study – among patients with atopic dermatitis and its frequent inclusion in personal care products misleadingly labeled as “hypoallergenic” for children [29, 52]. Zug and colleagues reported data on 883 children patch tested over a 7-year period, and compared allergens detected by the NACDG 65- or 70-series to those on the T.R.U.E. Test. They determined that of all the PPT detected by the NACDG series, 66% of these would have been detected if patients were solely evaluated with the T.R.U.E. Test [26]. Notably, this 66% reflected detection of 13 of the 15 most relevant PPT allergens in children. The authors concluded that the T.R.U.E. Test is a useful screening tool for pediatric ACD; however, clinicians need to be aware of common pediatric allergens that are not present on the T.R.U.E. Test panels, specifically those of higher clinical relevance such as propylene glycol and decyl glucoside [26]. This study also found that 23.6% of children had a PPT to a supplemental allergen that is not part of a standard patch testing series, reinforcing the importance of focused and specialized patch testing if initial testing is negative yet clinical suspicion for ACD remains high [26].

**Pediatric Baseline Series**

In an effort to improve patch testing procedures in children, the Pediatric Baseline Series (PBS) was proposed in 2018 [29, 52]. The PBS is based on survey and workgroup data collected from patch testing professionals and is the first comprehensive pediatric allergen panel in the United States. It is designed for use in children older than 6 years and includes 38 allergens with 2 additional spaces for allergens of the provider’s choice [53]. A study which examined the ability of the PBS and T.R.U.E. Test to diagnose pediatric ACD using PCDR data showed that the PBS was superior to T.R.U.E. Test in identifying PPT [54]. The authors posit...
this is due to the inclusion of common pediatric allergens in the PBS including methylisothiazolinone, propylene glycol, cocamidopropyl betaine, propolis, and iodopropynyl butylcarbamate [54].

No commercially available patch test panels carry an FDA indication for children under 6 years old; contact dermatitis experts can choose to use a commercially available patch test or create a customized one, though the latter necessitates greater infrastructure as it requires having a selection of allergens readily available in the patch testing clinic [5•, 52]. Additional, specialized patch test series have been created to evaluate for diaper dermatitis [50••].

In 2016, to reduce and proactively avoid pediatric ACD, the Pre-Emptive Avoidance Strategy (P.E.A.S.) was published. The P.E.A.S. was the result of a study attempting to quantify the effect of avoiding common allergens in personal care products. The authors generated a list of the top 10 allergens based on a systematic review of five studies of patch testing in children. The results suggested that if pediatric patients were to avoid the top 10 most common allergens in personal care products, it would likely prevent 33% of pediatric ACD cases. Hand-outs and cards were created (Table 4) listing products free of these 10 allergens. It was proposed that in conjunction with nickel avoidance and increased nickel surveillance and regulation, this could lead to a significant reduction in pediatric ACD. The P.E.A.S. can be used proactively in those wishing to avoid products with common allergens, or in targeted manner after patch testing has been completed. Despite the simplistic utility of P.E.A.S., it must be stressed that the gold standard in diagnosis, evaluation, and management of ACD is patch testing. Patch testing is the only diagnostic tool that can allow for definitive diagnosis of ACD, followed by specific avoidance of proven allergens. Patients patch tested by ACDS members may be provided with personalized lists of safe products from the ACDS CAMP database, which is regularly reviewed for accuracy and also includes educational materials prepared by contact dermatitis experts. There are also several online resources for patients to find “safe” products including SkinSAFE (SkinSafeProducts.com); however, this information must be carefully interpreted by the consumer as it is often created without physician consultation [16, 55].

**Practical Points About Pediatric Patch Testing**

The smaller surface area of the back in a pediatric patient can make physical application of patches more challenging. One author’s experience is that patients 2 to 4 years of age have space for application of between 40 and 45 allergens, while those 6 years old can accommodate 40–60 allergens [29, 52, 53].

There is limited evidence to suggest a decreased contact time or dilution of allergens for patch testing in children younger than 5–8 years old [5•, 29, 50••]. Our experience is to use standard contact times and concentrations in all of our pediatric patch tests, regardless of age. For children older than 12 years, traditional adult patch testing procedures are routinely recommended [29]. A hypoallergenic tape (Scanpor [SmartPractice], Phoenix, AZ) can be used to secure the patches and they can be reinforced with a stronger medical tape such as Hypafix (Smith and Nephew, Hato Rey, Puerto Rico) for extra security in highly active and mobile children [50••, 52]. Video cartoon distractions are helpful to

Table 4  Personal care products free of top 10 pediatric contact allergens

| Product type | Brand & product |
|--------------|----------------|
| Cleansers    | Albolene Moisturizing Cleanser Unscented, Aqua Glycolic Facial Cleanser, Bella Dry Skin Formula Moisturizing Body Bar, CeraVe Hydrating Cleanser, Cleure Glycerin Face/Body SLS Free Soap, DermaLah, Free and Clear, Magick Botanicals Unscented Bar Soap, Neutrogena Ultra Gentle Hydrating Cleanser, Vanicream Gentle Facial Cleanser, VMV Hypoallergenics Moisture Rich Creammmy Cleansing Milk for Dry Skin |
| Moisturizers | CeraVe Moisturizing Cream, Cetaphil Intensive Moisturizing Cream with Shea Butter, Cleure Body Lotion for Dry Sensitive Skin, Derma Topix Intensive Hand Cream, EltaMD Moisturizer Intense, Eucerin Professional Repair Extremely Dry Skin Lotion, Exederm Soothing Baby Oil, Glaxal base Moisturizing Cream; Magick Botanicals Oil Free Moisture Lotion, Neutrogena Norwegian Formula Hand Cream Fragrance-Free, Theraplex Emollient for Severely Dry Skin, TriCalm Clinical Repair Cream, Cheryl Lee MD Sensitive TrueLipids Relieve and Protect Ointment, Vaniply Ointment Dry Skin Care for Sensitive Skin, Vaseline Petroleum Jelly, VMV Hypoallergenics Hydra Balance Smart Moisturizer for Combination Skin |
| Shampoos     | AFM SafeChoice Shampoo and Body Wash, VMV Hypoallergenics Essence Skin Saving Clark Wash Hair + Body Big Softie Shampoo and Essence Skin-Saving Superwash Hair + Body Milk Shampoo |
| Conditioners | Cleure Replenishing Conditioner, DHS Conditioning Rinse with Penthenol, Free & Clear Hair Conditioner for Sensitive Skin, Magick Botanicals Spray on Detangler and Conditioner |
| Atopic dermatitis medications | A&D EpiCream Skin Barrier Emulsion, Aurstat Anti-Itch Hydrogel, Eletone Cream, Tetrix Cream |

Adapted from the P.E.A.S study Hill et al. [11•]
encourage patient cooperation during patch test placement [56].

**Repeat Open Application Testing**

Repeat Open Application Testing (R.O.A.T.) is a patch testing adjunct that entails the repeated application of a patient’s own personal care product in an attempt to elicit a positive reaction by simulating real-world use [50••, 52]. It can be used if a suspect allergen is not available for patch testing, if the patch test was negative despite high clinical suspicion, or to evaluate the safety of a new personal care product [30, 50••, 52]. R.O.A.T. is performed by applying a suspected allergen twice daily for 7–14 days to the volar forearm [30, 50••, 52]. Rinse-off products should be applied and rinsed off as they would be in daily practice [50••].

**Patch Testing on Immunosuppressants, Phototherapy, and Dupilumab**

It is generally accepted that systemic steroids dosed above 10–20 mg per day (in adults) and phototherapy within 1–2 weeks (within 6 weeks with the most conservative recommendations) of patch testing can blunt patch test results [50••, 57]. There is, however, a general lack of literature regarding the use of systemic agents and their effect on patch testing in children [30]. The European Academy of Allergy and Clinical Immunology (EAACI) position paper on patch testing in children acknowledges that little data exist on the effect of immunosuppressants on patch testing results. They recommend avoiding patch testing on immunosuppressives or phototherapy as it could mask weak reactions [58]. If this cannot be avoided, and if allergy is suspected despite negative results, alternative options would be re-testing or performing a delayed reading to capture late reactions [58].

Dupilumab, an injectable IL-4 receptor antagonist, is increasingly being used for the management of chronic dermatitis and recently received FDA approval for atopic dermatitis in children 6 years and above. The question of its effect on patch testing results is now even more salient. There are multiple small case series documenting the use of dupilumab to treat ACD and a clinical trial is actively recruiting adult patients with ACD who will undergo treatment with dupilumab [59]. One retrospective study evaluated the difference in patch testing results before and after dupilumab initiation [60]. Forty-eight patients with atopic dermatitis were included, with ages ranging from 17 to 92 years, many of whom had a childhood history of atopy [60]. The authors concluded that dupilumab did not uniformly weaken patch test results based on the change from definitely positive to definitely negative in only 13/125 patch test pairs [60].

A recent systematic review included 19 studies (72 patients) examining the effects of dupilumab on ACD and patch testing. Dupilumab resulted in clearance of ACD in some patients, partial improvement in a large proportion, and no improvement or worsening in others. Pre- and post-dupilumab patch test results were available in 144 instances: 17 positive patch tests were lost, 8 new reactions developed, and 71 were persistent (48 unknown). The effect of dupilumab on patch testing was variable; the authors posit this may be due to differential immune polarization of allergens [61]. While there is need for further investigation, the data thus far suggest that patch testing results are generally reliable during treatment with dupilumab. In cases of suspected ACD, it would be prudent to perform patch testing prior to starting therapy with dupilumab.

**Limitations and Potential Complications of Patch Testing**

Patch testing in children is safe and well tolerated. One rare potential complication of patch testing in patients with atopic dermatitis colonized by *Staphylococcus aureus* is the development of secondary bacterial infection, which was described by Admani et al. in a case series [62]. The authors propose preemptively using aseptic soaks (to be discontinued 4 days prior to patch testing) and avoidance of personal care products containing potential irritants such as cocamidopropyl betaine, fragrance, and formaldehyde to prevent this complication [62]. See Table 5 for further limitations and potential complications of pediatric patch testing.

Active sensitization is a rare adverse event that occurs when a patient undergoing patch testing develops contact

| Table 5 | Limitations and potential complications of pediatric patch testing |
|---------|---------------------------------------------------------------|
| False-positive irritant reactions | Poor adherence to protocol |
| Less body surface area for application of patches | Infection |
| Angry back syndrome (generalized hypersensitivity reaction around sites of applied patches) | Induction of allergy or sensitization through patch testing |

Neale et al. [2••, 50••], Admani et al. [62], Chen et al. [65]
allergy to a tested allergen [63]. This reaction is distinguished from a true PPT as it occurs more than 14 days after patch test placement, and can be confirmed with repeat patch testing. To date, there are no documented reports of active sensitization in children from patch testing [63].

“Angry back” or “excited skin” syndrome is a complication of patch testing in which false-positive reactions occur in close proximity to strong true-positives. The precise etiology of angry back syndrome is unclear; however, it may be due to a potent allergen inducing a state of hyperreactivity in the skin, or a preexisting dermatitis that lowers the threshold for cutaneous irritability. These false-positive reactions are not reproducible on subsequent patch testing, and can cause considerable confusion for patients who may be labeled as “multiple reactors” or are simply diagnosed with a flare of their underlying skin disease [64]. There is extremely limited data on “angry back syndrome” in children, though in general, children with extensive flaring of their dermatitis should defer patch testing until the flare has improved [65].

One major limitation to patch testing has always been a lack of providers qualified to administer the test and interpret its results. This is exemplified by the dearth of providers willing to perform pediatric patch testing, which is likely at least in part due to the now debunked fears regarding safety of patch testing in children [25, 63, 66, 67].

**Patch Testing and Telehealth**

The medical community has experienced a rapid expansion of telehealth in large part due to the COVID-19 pandemic. Even prior to the pandemic, however, a group of experts advocated for the development of a direct-to-consumer telehealth platform specifically for ACD [68].

A recent report described virtual patch testing performed for 10 patients during the COVID-19 pandemic [69]. Due to restrictions imposed by the government of New Zealand, these patients had a final patch test reading via telehealth [69]. Digital photography was used and the author specifically noted the use of “oblique photographs of individual patches” to help discern induration from epidermal change. Although the results were imperfect, this series provided evidence that virtual patch test reading can be considered, which would allow greater access to rural communities and patients/families without reliable transportation [69]. A more recent study compared the interpretation of patch test results between in-person evaluation and tele-dermatology evaluation. The outcomes included agreement in patch test results, reading interpretation, and final assessment (allergic, indeterminate, irritant, negative). Ultimately in-person and tele-dermatologists completely disagreed in the interpretation of patch test results for over 13% of patches at the second reading, and almost 25% for the final assessment. Failure did correlate with lower perceived quality of images, suggesting that one limitation of tele-dermatology for patch testing is the quality or resolution of the images provided [70]. There is a paucity of data regarding pediatric-specific virtual patch testing, with a single report in the English-language literature of a 15-year-old girl whose final assessment was performed via tele-dermatology [69]. We argue that further analyses of the utility of virtual patch testing should aim to include pediatric patients. The assessment of these cases is unique in that it would need to be done by a parent or caregiver and a cooperative child, which may add a further layer of complexity to the success of virtual patch testing.

**Conclusion**

This article seeks to address common misconceptions, challenges, and concerns regarding ACD in the pediatric population, while emphasizing the important role patch testing plays in its evaluation and management. Despite previous misconceptions, it is now recognized that ACD is not uncommon among children. Chronic, refractory, or atypical dermatitis in the pediatric patient warrants evaluation with appropriately targeted patch testing. Patch testing is safe and effective when the performing provider takes into consideration the nuances of such testing in a young patient, as well as the limitations of commercially available patch tests. There are continuously new and evolving contact allergens, as evidenced by the “unmasking” of allergens during the COVID-19 pandemic, and the advancement of technology leading to new avenues of allergen exposure, such as diabetes devices. The management of pediatric contact dermatitis requires a thorough evaluation, appreciation of patient-specific factors, and a measure of patience, which, when taken together, can lead to a satisfactory and treatment-altering diagnosis.

**Compliance with Ethical Standards**

**Conflict of Interest** The authors received no funding in the preparation of this manuscript. The authors have no conflicts of interest or competing interests to disclose.

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.
References

Papers of particular interest, published recently, have been highlighted as:

• Of importance

•• Of major importance

1. Leonard A, Guttman-Yassky E. The unique molecular signatures of contact dermatitis and implications for treatment. Clin Rev Allergy Immunol. 2019;56(1):1–8.

2. Neale H, Garza-Mayers AC, Tam I, Yu J. Pediatric allergic contact dermatitis. Part I: clinical features and common contact allergens in children. J Am Acad Dermatol. 2021;84(2):235–44. A helpful review article highlighting the most recent literature on common contact allergens in children.

3. Rundle CW, Presley CL, Militello M, Barber C, Powell DL, Jacob SE, et al. Hand hygiene during COVID-19: recommendations from the American Contact Dermatitis Society. J Am Acad Dermatol. 2020;83(6):1730–7.

4. Tam I, Yu J. Pediatric contact dermatitis: what’s new. Curr Opin Pediatr. 2020;32(4):524–30.

5. Borok J, Matiz C, Goldenberg A, Jacob SE. Contact dermatitis in atopic dermatitis children: past, present, and future. Clin Rev Allergy Immunol. 2019;56(1):86–98. A helpful review article that describes allergic contact dermatitis in children with atopic dermatitis including proposed mechanism of action, common allergens, and patch testing considerations.

6. Dhingra N, Shemer A, da Rosa JC, Rozenblit M, Fuentes-Duculan J, Gitter JK, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol. 2014;134(2):362–72. This basic science paper changed our fundamental understanding of the pathophysiology of allergic contact dermatitis by demonstrating contributions from inflammatory pathways apart from the Th1 pathway and highlighting that specific allergens may generate a different immune response.

7. BelloniFortina A, Caroppo F, Tadiotto CG. Allergic contact dermatitis in children. Expert Rev Clin Immunol. 2020;16(6):579–89.

8. Brod BA, Treat JR, Rothe MJ, Jacob SE. Allergic contact dermatitis: kids are not just little people. Clin Dermatol. 2015;33(6):605–12.

9. Lubbes S, Rustemeyer T, SillivesSmitt JH, Schutteelaar ML, Middelkamp-Hup MA. Contact sensitization in Dutch children and adolescents with and without atopic dermatitis—a retrospective analysis. Contact Dermat. 2017;76(3):151–9.

10. Aalinagli F, Bennike NH, Egeberg A, Thyssen JP, Johansen JD. Prevalence of contact allergy in the general population: a systematic review and meta-analysis. Contact Dermatitis. 2019;80(2):77–85.

11. Hill H, Goldenberg A, Golkar L, Beck K, Williams J, Jacob SE. Pre-Emptive Avoidance Strategy (P.E.A.S.)—addressing allergic contact dermatitis in pediatric populations. Expert Rev Clin Immunol. 2016;12(5):551–61. A review of the most common personal care products that cause allergic contact dermatitis with recommendations for avoidance strategies.

12. Jacob SE, Brankov N, Kerr A. Diagnosis and management of allergic contact dermatitis in children: common allergens that can be easily missed. Curr Opin Pediatr. 2017;29(4):443–7.

13. Brankov N, Jacob SE. Pre-emptive avoidance strategy 2016: update on pediatric contact dermatitis allergens. Expert Rev Clin Immunol. 2017;13(2):93–5.

14. Jacob SE, Goldenberg A, Pelletier JL, Fonacier LS, Usatine R, Silverberg N. Nickel allergy and our children’s health: a review of indexed cases and a view of future prevention. Pediatr Dermatol. 2015;32(6):779–85. A review of nickel contact allergy in children.

15. Warshaw EM, Aschenbeck KA, DeKoven JG, Maibach HI, Taylor JS, Sasseville D, et al. Piercing and metal sensitivity: extended analysis of the North American Contact Dermatitis Group Data 2007–2014. Dermat Contact Atopic Occup Drug. 2017;28(6):333–41.

16. Dumycz K, Kunkiel K, Feleszko W. Cosmetics for neonates and infants: hapten in products’ composition. Clin Transl Allergy. 2019;9:15.

17. Hamann CR, Bernard S, Hamann D, Hansen R, Thyssen JP. Is there a risk using hypoallergenic cosmetic pediatric products in the United States? J Allergy Clin Immunol. 2015;135(4):1070–1.

18. Hamann CR, Sahni S, Zug KA. Methylisothiazolinone: still on leave-on products, but no longer on baby wipes. Dermat Contact Atopic Occup Drug. 2019;30(2):173–4.

19. Kullberg SA, Gupta R, Warshaw EM. Methylisothiazolinone in children’s nail polish. Pediatr Dermatol. 2020;37(4):745–7.

20. Filippi F, Vincenzi C, Bruni F, Piraccini BM, La Placa M. Methylisothiazolinone is still used and underdeclared: a paediatric case of airborne contact dermatitis caused by water-based poster paints for children. Contact Dermatitis. 2020;82(4):260–1.

21. Sechi A, Vincenzi C, Tengattini V, Piraccini BM, Neri I, La Placa M. Airborne dermatitis in a child caused by isothiazolinones in a water-based paint in Italy: call for better regulations. Contact Dermat. 2018;79(1):45–6.

22. Anderson LE, Treat JR, Brod BA, Yu J. “Slime” contact dermatitis: case report and review of relevant allergens. Pediatr Dermatol. 2019;36(3):335–7.

23. BelloniFortina A, Fontana E, Peserico A. Contact sensitization in children: a retrospective study of 2,614 children from a single center. Pediatr Dermatol. 2016;33(4):399–404.

24. Collis RW, Sheinbein DM. Cocamidopropyl betaine is commonly found in hypoallergenic personal care products for children. J Am Acad Dermatol. 2020;82(5):1245–7.

25. Collis RW, Morris GM, Sheinbein DM, Coughlin CC. Expanded series and personalized patch tests for children: a retrospective cohort study. Dermat Contact Atopic Occup Drug. 2020;31(2):144–6.

26. Zug KA, Pham AK, Belsito DV, DeKoven JG, DeLeo VA, Fowler JF, et al. Patch testing in children from 2005 to 2012: results from the North American contact dermatitis group. Dermat Contact Atopic Occup Drug. 2014;24(6):345–55.

27. Jacob SE, Scheman A, McGowen MA. Propylene glycol. Dermat Contact Atopic Occup Drug. 2018;29(1):3–5.

28. Milam EC, Cohen DE. Contact dermatitis: emerging trends. Dermatol Clin. 2019;37(1):21–8.

29. Sindle A, Jacob SE, Martin K. Common allergens and considerations when performing pediatric patch testing. Dermatol Clin. 2020;38(3):321–7.

30. Tam I, Yu J. Allergic contact dermatitis in children: recommendations for patch testing. Curr Allergy Asthma Rep. 2020;20(9):41.

31. Jacob SE, McGowen M, Silverberg NB, Pelletier JL, Fonacier L, Mousdicas N, et al. Pediatric contact dermatitis registry data on contact allergy in children with atopic dermatitis. JAMA Dermatol. 2017;153(8):765–70. A retrospective review describing differences in ACD between pediatric patients with and without atopic dermatitis.

32. Rundle CW, Bergman D, Goldenberg A, Jacob SE. Contact dermatitis considerations in atopic dermatitis. Clin Dermatol. 2017;35(4):367–74.
33. Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218–33.

34. Kong C, Lam JM. Slime dermatitis. CMAJ Can Med Assoc J Assoc Med Assoc Can. 2019;191(19):E536.

35. Gittler JK, Garzon MC, Lauren CT. “Slime” may not be so benign: a cause of hand dermatitis. J Pediatr. 2018;200:288.

36. Amat-Samaranch V, Garcia-Melendo C, Tubau C, Puig L, Serra-Baldrich E. Occupational allergic contact dermatitis to isobornyl acrylate present in cell phone screen protectors. Contact Dermatitis. 2021;84(5):352–4.

37. Abbas M, Fiorillo L, Elliott JF. Right forearm eruption associated with playing minecraft: a case of contact dermatitis related to computer gaming. J Cutan Med Surg. 2018;22(2):234–5.

38. Hartsough EM, Hylwa SA. Wearable woes: allergens in diabetic devices. Dermat Contact Atopic Occup Drug. 2021;32(1):19–31.

39. Mine Y, Urakami T, Matsuura D. Allergic contact dermatitis caused by isobornyl acrylate when using the FreeStyle® Libre. J Diabetes Investig. 2019;10(5):1382–4.

40. Pyl J, Dendooven E, Van Eelen I, den Brinker M, Dotremont H, France A, et al. Prevalence and prevention of contact dermatitis caused by Freestyle Libre: a monocentric experience. Diabetes Care. 2020;43(4):918–20.

41. Lombardo F, Salzano G, Ciasullucci G, Panasiti I, Alibrandi A, Messina MF, et al. Allergic contact dermatitis in pediatric patients with type 1 diabetes: an emerging issue. Diabetes Res Clin Pract. 2020;162:108089.

42. Raison-Peyron N, Mowitz M, Bonardel N, Aerts O, Bruze M. Allergic contact dermatitis caused by isobornyl acrylate in OmniPod, an innovative tubeless insulin pump. Contact Dermatitis. 2018;79(2):76–80.

43. Oppel E, Kamann S, Heinemann L, Klein A, Reichl F-X, Hög C. Freestyle Libre 2: the new isobornyl acrylate free generation. Contact Dermatitis. 2020;83(5):429–31.

44. Kamann S, Oppel E. Hydrocolloid blister plaster decreases allergic contact dermatitis caused by Freestyle Libre and isobornyl acrylate. Contact Dermatitis. 2019;81(5):380–1.

45. Kamann S, Heinemann L, Oppel E. Usage of hydrocolloid-based plasters in patients who have developed allergic contact dermatitis to isobornyl acrylate while using continuous glucose monitoring systems. J Diabetes Sci Technol. 2020;14(3):582–5.

46. de Groot A. Limonene hydroperoxides. Dermat Contact Atopic Occup Drug. 2019;30(4):243–6.

47. de Groot A. Limonene hydroperoxides. Dermat Contact Atopic Occup Drug. 2019;30(6):331–5.

48. Moustafa D, Yu J. Contact allergy to hydroperoxides of limonene and linalool in a pediatric population. J Am Acad Dermatol. 2020;83(3):946–7.

49. Besner Morin C, Stanciu M, Miedzybrodzki B, Sasseville D. Allergic contact dermatitis from acetophenone azine in a Canadian child. Contact Dermatitis. 2020;83(1):41–2.

50. Neale H, Garza-Mayers AC, Tam I, Yu J. Pediatric allergic contact dermatitis Part 2: patch testing series, procedure, and unique scenarios. J Am Acad Dermatol. 2021;84(2):247–55. A helpful review article highlighting the most salient practical implications for pediatric patch testing.

51. Shaughnessy CN, Malajian D, Belsito DV. Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis: reactivity to surfactants. J Am Acad Dermatol. 2014;70(4):704–8.

52. Sung CT, McGowan MA, Jacob SE. Allergic contact dermatitis evaluation: strategies for the preschooler. Curr Allergy Asthma Rep. 2018;18(10):49.

53. Yu J, Atwater AR, Brod B, Chen JK, Chisolm SS, Cohen DE, et al. Pediatric baseline patch test series: pediatric contact dermatitis workgroup. Dermat Contact Atopic Occup Drug. 2018;29(4):206–12.

54. Tam I, Gole H, Martin KL, Goldminz AM, Yu J. Cross-sectional evaluation of the pediatric baseline series in detection of contact sensitization in children. J Am Acad Dermatol. 2021;84(4):1123–6.

55. Yu J, Treat J, Chaney K, Brod B. Potential allergens in disposable diaper wipes, topical diaper preparations, and disposable diapers: under-recognized etiology of pediatric perineal dermatitis. Dermat Contact Atopic Occup Drug. 2016;27(3):110–8.

56. Jacob SE. Avoid the shriek with Shrek: video-distraction assist for pediatric patch testing. Dermat Contact Atopic Occup Drug. 2007;18(3):179–80.

57. Daughton A, Williams J. The impact of ultraviolet exposure on patch testing in clinical practice: a case-control study. Clin Exp Dermatol. 2020;45(1):25–9.

58. de Waard-van der Spek FB, Darsow U, Mortz CG, Orton D, Worm M, Muraro A, et al. EAACI position paper for practical patch testing in allergic contact dermatitis in children. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2015;26(7):598–606.

59. Chipalkatti N, Lee N, Zancanaro P, Dumont N, Kachuk C, Rosmarin D. A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis. J Am Acad Dermatol. 2019;80(4):1166–7.

60. Rafi J, Suresh R, Botto N, Murase JE. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review. J Am Acad Dermatol. 2020;82(1):132–8.

61. Jo CE, Mufti A, Sachdeva M, Pratt M, Yeung J. Effect of dupilumab on allergic contact deramitis and patch testing. J Am Acad Dermatol. 2021;84(6):1772–6.

62. Admani S, Matiz C, Jacob SE. Countering Staphylococcus overgrowth during patch testing in children with moderate to severe atopic dermatitis. Pediatr Dermatol. 2016;33(1):56–61.

63. Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing—recommendations on best practice. Contact Dermatitis. 2015;73(4):195–221.

64. Cockayne SE, Gawkrodger DJ. Angry back syndrome is often due to marginal irritants: a study of 17 cases seen over 4 years. Contact Dermatitis. 2000;43(5):280–2.

65. Chen JK, Jacob SE, Nedorost ST, Hanifin JM, Simpson EL, Boguniewicz M, et al. A pragmatic approach to patch testing atopic dermatitis patients: clinical recommendations based on expert consensus opinion. Dermat Contact Atopic Occup Drug. 2016;27(4):186–92.

66. Pelletier JL, Perez C, Jacob SE. Contact dermatitis in pediatrics. Pediatr Ann. 2016;45(8):e287–92.

67. Jacob SE, Herro EM, Sullivan K, Matiz C, Eichenfield L, Hamann C. Safety and efficacy evaluation of TRUE TEST panels 1.1, 2.1, and 3.1 in children and adolescents. Dermat Contact Atopic Occup Drug. 2011;22(4):204–10.

68. Jacob SE, Gut P, Goldenberg A. DTC teledermatology: access to the specialists’ specialist—meeting an unmet need. J Telemed Telecare. 2017;23(4):494–6.

69. Cheng HS. Patch testing interrupted: virtual patch test readings during the COVID-19 pandemic. Dermat Contact Atopic Occup Drug. 2020;31(4):e35–6.

70. Goodier MC, DeKoven JG, Taylor JS, Sasseville D, Fowler JF, Fransway AF, et al. Inter-rater variability in patch test readings and final interpretation using store-forward teledermatology. Contact Dermatitis. 2021;85(3):274–84.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.